Indication
Lucentis is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to choroidal neovascularisation (CNV) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- LucentisBrazil · Novartis Biociencias S.ASame brand
- LucentisCanada · 10 MG / ML · Solution · Novartis Pharmaceuticals Canada INC · 2 entriesSame brand
- Lucentis 10 MG/ML Solucion InyectableSpain · 2,3 mg · solución inyectable · Novartis Europharm LimitedSame brand
- Lucentis 10 MG/ML Solucion Inyectable en Jeringa Precargada